144 related articles for article (PubMed ID: 9488603)
21. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
[TBL] [Abstract][Full Text] [Related]
22. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.
Nielsen D; Dombernowsky P; Larsen SK; Hansen OP; Skovsgaard T
Cancer Chemother Pharmacol; 2000; 46(6):459-66. PubMed ID: 11138459
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Pacetti U; Carlini P; Ruggeri EM; Cognetti F
Cancer Chemother Pharmacol; 2001 Sep; 48(3):255-8. PubMed ID: 11592349
[TBL] [Abstract][Full Text] [Related]
25. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
26. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergström D; Ahlgren J
Eur J Cancer; 2007 May; 43(7):1153-60. PubMed ID: 17398088
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
29. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
30. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
31. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
[TBL] [Abstract][Full Text] [Related]
33. Combination of epirubicin and lonidamine for treatment of advanced breast cancer.
Moraglio L; Brema F; Pastorino G; Martini MC; Vallauri M
Tumori; 1995; 81(2):107-11. PubMed ID: 7778213
[TBL] [Abstract][Full Text] [Related]
34. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Lopez M; Vici P; Di Lauro L; Paoletti G; Gionfra T; Conti F; Carpano S; Pignatti F; Giannarelli D
Eur J Cancer; 1995 Sep; 31A(10):1611-4. PubMed ID: 7488410
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S
J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387
[TBL] [Abstract][Full Text] [Related]
36. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
[TBL] [Abstract][Full Text] [Related]
37. Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: a phase II study.
Portalone L; Lombardi A; Antilli A; Cruciani AR; Magliacani V; Mugnaini L; Nunziati F; Perrone N; Signora M; Salvati F
Tumori; 1999; 85(4):239-42. PubMed ID: 10587024
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Chen X; Oza AM; Kusenda Z; Yi QL; Kochman D; Moore MJ; Davis AJ; Siu LL
Br J Cancer; 2003 Aug; 89(4):617-24. PubMed ID: 12915867
[TBL] [Abstract][Full Text] [Related]
39. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
40. Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Zaniboni A; Montini E; Simoncini E; Marpicati P; Arcangeli G; Meriggi F; Marini G
Am J Clin Oncol; 1990 Dec; 13(6):520-3. PubMed ID: 2122716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
